WuXi AppTec (inactive)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From WuXi AppTec (inactive)
Biotech CEO Interview: Harbour BioMed's Wang On Moderna Deal, New Subsidiary
After inking major deals with AbbVie and AstraZeneca, China-US company Harbour BioMed recently shifted strategy, divesting its site in Suzhou to WuXi in a bid to be “more focused, efficient and nimble” and emerge stronger post-pandemic, says founder, chairman and CEO Jingsong Wang in an exclusive interview.
BeiGene, Zai Lab Look To Clear US Delisting Uncertainties
US-listed Chinese biotechs are switching auditors in hopes of satisfying the US securities regulator's demands - but legal experts also see other considerations at play.
US Puts China's WuXi Biologics On New Export Restriction List
The latest move signals a toughening stance in China over sensitive technology exports, as the bilateral relationship with the US continues its free fall.
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
- Contract Research Organization-CRO
- Medical Devices
- Contract Manufacturing Organization
- Gene Therapy, Cell Therapy
Drug Discovery Technologies
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.